NASDAQ:CLSN

Celsion Stock Forecast, Price & News

$1.27
+0.07 (+5.37 %)
(As of 04/13/2021 02:33 PM ET)
Add
Compare
Today's Range
$1.17
Now: $1.28
$1.31
50-Day Range
$1.35
MA: $1.88
$2.81
52-Week Range
$0.43
Now: $1.28
$6.50
Volume64,960 shs
Average Volume18.45 million shs
Market Capitalization$95.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42
Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Celsion logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSN
CUSIPN/A
Phone(609) 896-9100
Employees29
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.63 per share

Profitability

Net Income$-16,850,000.00
Net Margins-4,315.00%

Miscellaneous

Market Cap$95.65 million
Next Earnings Date5/21/2021 (Estimated)
OptionableOptionable

Headlines

Celsion (NASDAQ:CLSN) Announces Earnings Results
March 20, 2021 |  americanbankingnews.com
Form S-3 Celsion CORP - StreetInsider.com
March 20, 2021 |  streetinsider.com
Celsion Posts Wider Loss In FY20
March 19, 2021 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

849th out of 2,016 stocks

Pharmaceutical Preparations Industry

407th out of 771 stocks

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.27
+0.07 (+5.37 %)
(As of 04/13/2021 02:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Celsion (NASDAQ:CLSN) Frequently Asked Questions

Is Celsion a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Celsion stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLSN, but not buy additional shares or sell existing shares.
View analyst ratings for Celsion
or view top-rated stocks.

What stocks does MarketBeat like better than Celsion?

Wall Street analysts have given Celsion a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Celsion wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Celsion?

Celsion saw a increase in short interest during the month of February. As of February 26th, there was short interest totaling 3,710,000 shares, an increase of 78.4% from the February 11th total of 2,080,000 shares. Based on an average daily volume of 18,460,000 shares, the short-interest ratio is currently 0.2 days. Currently, 6.2% of the company's shares are short sold.
View Celsion's Short Interest
.

When is Celsion's next earnings date?

Celsion is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Celsion
.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) issued its earnings results on Thursday, March, 18th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.08. Celsion had a negative net margin of 4,315.00% and a negative trailing twelve-month return on equity of 104.32%.
View Celsion's earnings history
.

How has Celsion's stock been impacted by COVID-19?

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLSN shares have increased by 28.8% and is now trading at $1.2750.
View which stocks have been most impacted by COVID-19
.

When did Celsion's stock split? How did Celsion's stock split work?

Shares of Celsion reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CLSN?

2 Wall Street analysts have issued 1-year target prices for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 213.7% from the stock's current price.
View analysts' price targets for Celsion
or view top-rated stocks among Wall Street analysts.

Who are Celsion's key executives?

Celsion's management team includes the following people:
  • Michael H. Tardugno, Chairman, President & Chief Executive Officer
  • Jeffrey Wayne Church, CFO, Secretary & SVP-Investor Relations
  • Nicholas Borys, Chief Medical Officer & Senior Vice President
  • Khursheed Anwer, Chief Scientific Officer & Executive VP
  • Jason G. Fewell, Vice President-Preclinical Research

Who are some of Celsion's key competitors?

What other stocks do shareholders of Celsion own?

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $1.28.

How much money does Celsion make?

Celsion has a market capitalization of $95.65 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does Celsion have?

Celsion employs 29 workers across the globe.

What is Celsion's official website?

The official website for Celsion is www.celsion.com.

Where are Celsion's headquarters?

Celsion is headquartered at 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.